Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Faezeh Tatari, Vahid Farnia, Fatemeh Lalehgni, Asieh Moradi, Farnaz Radmehr, Omran Davarinejad, Sara Hookari, Safora Salemi, Farzaneh Golmohammadi & Mostafa Alikhani. (2022) The efficacy of venlafaxine in the treatment of depression, withdrawal symptoms, and craving in individuals with methamphetamine dependence. Journal of Substance Use 0:0, pages 1-9.
Read now
Read now
Gustavo A. Angarita, Hasti Hadizadeh, Ignacio Cerdena & Marc N. Potenza. (2021) Can pharmacotherapy improve treatment outcomes in people with co-occurring major depressive and cocaine use disorders?. Expert Opinion on Pharmacotherapy 22:13, pages 1669-1683.
Read now
Read now
Kathleen M. Carroll & Bruce J. Rounsaville. (2007) A Perfect Platform: Combining Contingency Management with Medications for Drug Abuse. The American Journal of Drug and Alcohol Abuse 33:3, pages 343-365.
Read now
Read now
Kathleen T. Brady & Marcia L. Verduin. (2005) Pharmacotherapy of Comorbid Mood, Anxiety, and Substance Use Disorders. Substance Use & Misuse 40:13-14, pages 2021-2041.
Read now
Read now
Articles from other publishers (38)
Zhenxiang Gao, T. John Winhusen, Maria Gorenflo, Udi E. Ghitza, Edward Nunes, Andrew J. Saxon, Todd Korthuis, Kathleen Brady, Sean Luo, Pamela B. Davis, David C. Kaelber & Rong Xu. (2023) Potential effect of antidepressants on remission from cocaine use disorder – A nationwide matched retrospective cohort study. Drug and Alcohol Dependence 251, pages 110958.
Crossref
Crossref
Medhat M. Bassiony, Nelly R. Abdelfattah, Amany Elshabrawy & Mary M. Adly. (2023) A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol. International Clinical Psychopharmacology.
Crossref
Crossref
Patricia M. Richey, Leah Laageide & Brian L. Swick. (2022) Stimulant use in patients presenting with psychocutaneous disorders. Journal of the American Academy of Dermatology 86:5, pages 1002-1009.
Crossref
Crossref
Jonathan Henssler, Lasse Brandt, Andreas Heinz & Martin Schäfer. 2022. Therapieresistenz bei Depressionen und bipolaren Störungen. Therapieresistenz bei Depressionen und bipolaren Störungen
85
101
.
Giulia Francesconi, Laura Orsolini, Duccio Papanti, John M. Corkery & Fabrizio Schifano. (2015) Venlafaxine as the ‘baby ecstasy’? Literature overview and analysis of web-based misusers′ experiences. Human Psychopharmacology: Clinical and Experimental 30:4, pages 255-261.
Crossref
Crossref
Wilfrid Noel Raby, Eric A. Rubin, Fatima Garawi, Wendy Cheng, Ella Mason, Lisa Sanfilippo, Stephanie Lord, Adam Bisaga, Efrat Aharonovich, Frances Levin, David McDowell & Edward V. Nunes. (2014) A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. The American Journal on Addictions 23:1, pages 68-75.
Crossref
Crossref
Pier Paolo Pani, Emanuela Trogu, Simona Vecchi & Laura Amato. (2011) Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database of Systematic Reviews.
Crossref
Crossref
John A. Renner, Jeffrey Baxter, Joji Suzuki & Domenic A. Ciraulo. 2011. Pharmacotherapy of Depression. Pharmacotherapy of Depression
239
274
.
T.R. Kosten & D.E. Davis. 2010. Encyclopedia of Behavioral Neuroscience. Encyclopedia of Behavioral Neuroscience
308
316
.
Manoranjan S. D’Souza & Athina Markou. 2010. Behavioral Neuroscience of Drug Addiction. Behavioral Neuroscience of Drug Addiction
119
178
.
Katsumasa Muneoka, Yukihiko Shirayama, Morikuni Takigawa & Seiji Shioda. (2008) Brain Region-Specific Effects of Short-Term Treatment with Duloxetine, Venlafaxine, Milnacipran and Sertraline on Monoamine Metabolism in Rats. Neurochemical Research 34:3, pages 542-555.
Crossref
Crossref
Bridget Candy, Louise Jones, Rachael Williams, Adrian Tookman & Michael King. (2008) Psychostimulants for depression. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Shih-Ku Lin, Chia-Hui Chen & Chun-Hung Pan. (2008) Venlafaxine for Acute Heroin Detoxification. Journal of Clinical Psychopharmacology 28:2, pages 189-194.
Crossref
Crossref
Quyen Q. Tiet & Brent Mausbach. (2007) Treatments for Patients With Dual Diagnosis: A Review. Alcohol: Clinical and Experimental Research 31:4, pages 513-536.
Crossref
Crossref
Neil E. Paterson & Athina Markou. (2007) Animal models and treatments for addiction and depression co-morbidity. Neurotoxicity Research 11:1, pages 1-32.
Crossref
Crossref
Shih-Jen Tsai. (2007) Increased central brain-derived neurotrophic factor activity could be a risk factor for substance abuse: Implications for treatment. Medical Hypotheses 68:2, pages 410-414.
Crossref
Crossref
John C.M. Brust. 2007. Aspects neurologiques de l'addiction. Aspects neurologiques de l'addiction
171
243
.
David McDowell, Edward V. Nunes, Angela M. Seracini, Jami Rothenberg, Suzanne K. Vosburg, Guoguang J. Ma & Eva Petkova. (2005) Desipramine treatment of cocaine-dependent patients with depression: A placebo-controlled trial. Drug and Alcohol Dependence 80:2, pages 209-221.
Crossref
Crossref
Domenic A. Ciraulo, Ofra Sarid‐Segal, Clifford M. Knapp, Ann Marie Ciraulo, Joseph LoCastro, Daniel A. Bloch, Margaret A. Montgomery, Deborah B. Leiderman & Ahmed Elkashef. (2005) Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. Addiction 100:s1, pages 12-22.
Crossref
Crossref
Domenic A. Ciraulo, Clifford Knapp, John Rotrosen, Ofra Sarid‐Segal, Ann Marie Ciraulo, Joseph LoCastro, David J. Greenblatt & Deborah Leiderman. (2005) Nefazodone treatment of cocaine dependence with comorbid depressive symptoms. Addiction 100:s1, pages 23-31.
Crossref
Crossref
Paul M. Cinciripini, Janice Y. Tsoh, David W. Wetter, Cho Lam, Carl de Moor, Lynn Cinciripini, Walter Baile, Cheryl Anderson & John D. Minna. (2005) Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation.. Experimental and Clinical Psychopharmacology 13:4, pages 282-292.
Crossref
Crossref
Xavier Camarasa, Elena Lopez-Martinez, Annik Duboc, Yasser Khazaal & Daniele Fabio Zullino. (2005) Escitalopram/reboxetine combination in depressed patients with substance use disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 29:1, pages 165-168.
Crossref
Crossref
Alasdair M. Barr & Athina Markou. (2005) Psychostimulant withdrawal as an inducing condition in animal models of depression. Neuroscience & Biobehavioral Reviews 29:4-5, pages 675-706.
Crossref
Crossref
M. Schäfer & A. Heinz. 2005. Akute und therapieresistente Depressionen. Akute und therapieresistente Depressionen
91
104
.
Hugh Myrick, Jeff Cluver, Steve Swavely & Hamilton Peters. (2004) Diagnosis and treatment of co-occurring affective disorders and substance use disorders. Psychiatric Clinics of North America 27:4, pages 649-659.
Crossref
Crossref
Thomas R. Kosten & Therese A. Kosten. (2004) New medication strategies for comorbid substance use and bipolar affective disorders. Biological Psychiatry 56:10, pages 771-777.
Crossref
Crossref
A. R. Lingford-Hughes, S. Welch & D. J. Nutt. (2016) Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 18:3, pages 293-335.
Crossref
Crossref
Kathleen M Carroll, Thomas R Kosten & Bruce J Rounsaville. (2004) Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug and Alcohol Dependence 75:2, pages 123-134.
Crossref
Crossref
John C.M. Brust. 2004. Neurological Aspects of Substance Abuse. Neurological Aspects of Substance Abuse
139
199
.
John A. RennerJr.Jr., Jeffrey D. Baxter & Domenic A. Ciraulo. 2004. Pharmacotherapy of Depression. Pharmacotherapy of Depression
211
241
.
Michael P Bogenschutz & Cynthia M.A Geppert. (2003) Pharmacologic treatments for women with addictions. Obstetrics and Gynecology Clinics of North America 30:3, pages 523-544.
Crossref
Crossref
Gilberto Gerra, Mila Ferri, Edoardo Polidori, Giovanna Santoro, Amir Zaimovic & Emilio Sternieri. (2003) Long-term methadone maintenance effectiveness: psychosocial and pharmacological variables. Journal of Substance Abuse Treatment 25:1, pages 1-8.
Crossref
Crossref
Stuart M White & Cheryl J.T Lambe. (2003) The pathophysiology of cocaine abuse. Journal of Clinical Forensic Medicine 10:1, pages 27-39.
Crossref
Crossref
Richard W. Foltin, Amie S. Ward, Eric D. Collins, Margaret Haney, Carl L. Hart & Marian W. Fischman. (2003) The effects of venlafaxine on the subjective, reinforcing, and cardiovascular effects of cocaine in opioid-dependent and non-opioid-dependent humans.. Experimental and Clinical Psychopharmacology 11:2, pages 123-130.
Crossref
Crossref
Alasdair M Barr, Athina Markou & Anthony G Phillips. (2002) A ‘crash’ course on psychostimulant withdrawal as a model of depression. Trends in Pharmacological Sciences 23:10, pages 475-482.
Crossref
Crossref
Charles A. Dackis & Charles P. OʼBrien. (2002) Cocaine dependence: the challenge for pharmacotherapy. Current Opinion in Psychiatry 15:3, pages 261-267.
Crossref
Crossref
Igor ElmanKatherine H. Karlsgodt, David R. Gastfriend, Christopher F. Chabris & Hans C. Breiter. (2016) Cocaine-primed craving and its relationship to depressive symptomatology in individuals with cocaine dependence. Journal of Psychopharmacology 16:2, pages 163-167.
Crossref
Crossref
Grace O’Leary & Roger D. Weiss. (2000) Pharmacotherapies for cocaine dependence. Current Psychiatry Reports 2:6, pages 508-513.
Crossref
Crossref